Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P39060 (
endostatin
)
2,284
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Angiogenesis, an essential process for tumor growth, is regulated by endothelial proliferation factors and their inhibitors such as
endostatin
. Endostatin, a carboxyl-terminal fragment of
type XVIII collagen
, inhibits endothelial proliferation, angiogenesis, and tumor growth.
Ornithine decarboxylase
(
ODC
), a molecule that is overexpressed in various cancers, is associated with promoting tumor growth and angiogenesis. We found that
ODC
-overexpressing human cancer cells and breast cancer specimens showed suppressed expression of
type XVIII collagen
and
endostatin
. We hypothesized that
ODC
overexpression may facilitate angiogenesis in tumors by suppressing
endostatin
expression.
ODC
-overexpressing COS cells, which showed suppressed
type XVIII collagen
and
endostatin
expression, were established. Conditioned media derived from these cells, containing decreased levels of
endostatin
, induced significant endothelial proliferation.
ODC
-overexpressing cells, when transplanted into nude mice, suppressed
type XVIII collagen
expression and promoted neovascularization in vivo. Thus, overexpression of
ODC
facilitates endothelial proliferation by suppressing
endostatin
expression.
...
PMID:Overexpression of ornithine decarboxylase enhances endothelial proliferation by suppressing endostatin expression. 1183 May 3
Cancer is a global health problem and chemoprevention is a promising approach for reducing cancer burden. Inositol hexaphosphate (IP6), a natural bioactive constituent of cereals, legumes, etc., has momentous potential as an
antiangiogenic agent
, that specifically affects malignant cells. The shortcoming is its quick absorption on oral/topical administration. Niosomes are flexible carriers for topical drug delivery. The central venture of current research was to optimize and characterize niosomal delivery system of IP6 for treatment of skin cancer. Thin film hydration method was utilized to prepare IP6 niosomes, and these were dispersed as a suspension in a suitable base. Developed formulations were analyzed for various physicochemical and pharmacological parameters such as particle size, encapsulation efficiency, morphology, drug release, texture analysis, irritability, cell line studies, Western blotting, RT-PCR, and histopathology. IP6 niosomal suspension and IP6 in acetone displayed IC
50
value at the concentration of 0.96 mM (0.63 mg/mL) and 1.39 mM (0.92 mg/mL), respectively. IP6 niosomal suspension showed significantly higher (p < 0.05) activity and showed cytotoxic effect in SK-MEL-2 cancer cell line. Crucial events of cellular proliferation and differentiation, like expression of
ornithine decarboxylase
(
ODC
), proliferating cell nuclear antigen (PCNA), cycloxygenase-2 (COX-2) and Cyclin D1 were initiated from the fourth hour through application of 7,12-dimethylbenzanthracene (DMBA) on albino mice. The DMBA altered expression of aforesaid enzymes was significantly (P < 0.001) prevented by concomitant application of niosomal formulations. Results of cell line study, Western blotting, RT-PCR, and histopathology suggested that IP6 niosomal suspension could constitute a promising approach for prevention of cellular proliferation as well as DMBA induced dysregulation of cellular proliferation/differentiation and inflammation.
...
PMID:Colloidal Vesicular System of Inositol Hexaphosphate to Counteract DMBA Induced Dysregulation of Markers Pertaining to Cellular Proliferation/Differentiation and Inflammation of Epidermal Layer in Mouse Model. 2816 46
